| Product Name: | Valrubicin Powder |
|---|---|
| Appearance: | White Powder |
| Test: | HPLC |
| Mf: | C34h36f3no13 |
| CAS: | 56124-62-0 |
| MW: | 732.64 |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
99% High Pure Valrubicin Powder CAS 56124-62-0 Raw Materials Purity Valrubicin
| Product Name | 99% High Pure Valrubicin Powder CAS 56124-62-0 Raw Materials Purity Valrubicin |
| CAS | 56124-62-0 |
| Appearance | white Powder |
| Molecular formula | C34H36F3NO13 |
| Molecular Weight | 732.64 |
| Assay | 98% |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
|
What is Valrubicin?Valrubicin is a chemotherapy drug used to treat bladder cancer.Valrubicin is a chemotherapeutic agent used in the treatment of bladder cancer. Valrubicin inhibited TPA-and PDBU-induced PKC activation with IC50 values of 0.85 μM and 1.25 μM, respectively. |
Valrubicin was launched as a new 'chemotherapeutic agent for the treatment of bladder cancer, particularly in
patients with BCG-refractory carcinoma in situ (CIS) of the bladder for whom immediate cystectomy is unacceptable.
It belongs to the class of anthracyclines, the widest used in human cancers, and is a N-trifluoroacetyl 14-valerate
derivative.
Valrubicin can be obtained in 3 steps from daunomycin by N-trifluoroacetylation of the sugar moiety then iodination
of the 2-acetyl group and introduction of a valerate residue. A proposed mechanism involved in the cytotoxicity of
Valrubicin coud be the blockade of SV40 large T antigen helicase; this cellular enzyme is involved in the formation of
a ternary complex with DNA to maintain the topographic structure of DNA during transcription.
In patients with CIS of bladder refractory to front line and second line therapies, intravesical instillation of Valrubicin
resulted in a complete response with a significant rate and allowed a delay in cystectomy. Systemic absorption was
minimal and accordingly produced a lower incidence of cardiotoxicity compared.
Valrubicin is available in 200-mg vials for intravesicular administrationin the treatment of bladder cancer (orphan
drugstatus). The increased lipophilicity associated with the valericacid ester and trifluoro acetate functionalities
increasestissue penetration and remains intact because, in large measure,of the lack of exposure to hydrolyzing
enzymes causedby direct delivery into the bladder followed by voiding ofthe instilled solution. This local action also
minimizes cardiotoxicityand other adverse effects seen with other anthracyclines.The major adverse effects that
are seen are bladderirritation and reddening of the urine.
99% High Pure Valrubicin Powder CAS 56124-62-0 Raw Materials Purity Valrubicin
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}